Multicentre Study Comparing Indwelling Pleural Catheter With Talc Pleurodesis for Malignant Pleural Effusion Management
Launched by NATIONAL UNIVERSITY HOSPITAL, SINGAPORE · Jan 22, 2014
Trial Information
Current as of June 28, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Symptomatic malignant pleural effusion requiring intervention
- Exclusion Criteria:
- • \<18 years of age
- • pregnant or lactating patients
- • expected survival \<3 months
- • chylothorax
- • previous attempted pleurodesis
- • pleural infection
- • leukocytopaenia (\<1.0 x 10\^9/L)
- • uncorrectable bleeding diathesis
- • inability to give informed consent or comply with the protocol
About National University Hospital, Singapore
National University Hospital (NUH) in Singapore is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, NUH emphasizes a multidisciplinary approach, integrating cutting-edge medical research with high-quality patient care. The hospital collaborates with various stakeholders, including academic institutions and industry partners, to explore new therapies and improve treatment outcomes across a wide range of medical disciplines. Committed to ethical standards and patient safety, NUH plays a pivotal role in shaping the future of medicine in Singapore and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Singapore, , Singapore
Patients applied
Trial Officials
Pyng Lee, MBBS, MRCP, MMED, FAMS, FCCP
Principal Investigator
National University of Singapore
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials